Joshua P. Vanderloo

479 total citations
11 papers, 359 citations indexed

About

Joshua P. Vanderloo is a scholar working on Infectious Diseases, Molecular Biology and Clinical Biochemistry. According to data from OpenAlex, Joshua P. Vanderloo has authored 11 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Infectious Diseases, 5 papers in Molecular Biology and 3 papers in Clinical Biochemistry. Recurrent topics in Joshua P. Vanderloo's work include Prion Diseases and Protein Misfolding (4 papers), Bacterial Identification and Susceptibility Testing (3 papers) and Trace Elements in Health (3 papers). Joshua P. Vanderloo is often cited by papers focused on Prion Diseases and Protein Misfolding (4 papers), Bacterial Identification and Susceptibility Testing (3 papers) and Trace Elements in Health (3 papers). Joshua P. Vanderloo collaborates with scholars based in United States, Ireland and Canada. Joshua P. Vanderloo's co-authors include Chad Johnson, Debbie McKenzie, Judd M. Aiken, Delwyn P. Keane, Jody Johnson, Allen Herbst, Rick Chappell, Jill Kolesar, Lee C. Vermeulen and Marcia Pomplun and has published in prestigious journals such as PLoS ONE, Antimicrobial Agents and Chemotherapy and Journal of General Virology.

In The Last Decade

Joshua P. Vanderloo

11 papers receiving 351 citations

Peers

Countries citing papers authored by Joshua P. Vanderloo

Since Specialization

Citations

This map shows the geographic impact of Joshua P. Vanderloo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua P. Vanderloo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua P. Vanderloo more than expected).

Fields of papers citing papers by Joshua P. Vanderloo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua P. Vanderloo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua P. Vanderloo. The network helps show where Joshua P. Vanderloo may publish in the future.

Co-authorship network of co-authors of Joshua P. Vanderloo

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua P. Vanderloo. A scholar is included among the top collaborators of Joshua P. Vanderloo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua P. Vanderloo. Joshua P. Vanderloo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Effectiveness and Safety of Albuterol Solutions With and Without Benzalkonium Chloride 2023 ·Respiratory Care ·Awni Al‐Subu, (unknown), (unknown), (unknown), (unknown), (unknown), Michael Lasarev, (unknown), Joshua P. Vanderloo, (unknown)	2
2	Remdesivir Use in Pediatric Patients for SARS-CoV-2 Treatment: Single Academic Center Study 2022 ·The Pediatric Infectious Disease Journal ·(unknown), (unknown), (unknown), (unknown), Lucas Schulz, (unknown), Joshua P. Vanderloo, Pelin Cengiz, Sheryl L. Henderson	11
3	Nirmatrelvir‐ritonavir treatment of COVID‐19 in a high‐risk patient population: A retrospective observational study 2022 ·JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Joshua P. Vanderloo, Lucas Schulz	7
4	Comprehensive Care Improvement for Oncologic Fever and Neutropenia from a Pediatric Emergency Department 2021 ·Pediatric Quality and Safety ·(unknown), Erin K McCreary, Sheryl L. Henderson, Joshua P. Vanderloo, (unknown), (unknown), (unknown)	1
5	Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience 2020 ·Drugs - Real World Outcomes ·(unknown), (unknown), Erin K McCreary, Joshua P. Vanderloo, Erika J. Ernst, (unknown), Lucas Schulz	19
6	Vancomycin Tolerance in Methicillin-Resistant Staphylococcus aureus: Influence of Vancomycin, Daptomycin, and Telavancin on Differential Resistance Gene Expression 2012 ·Antimicrobial Agents and Chemotherapy ·Warren E. Rose, Michael J. Fallon, John J. Moran, Joshua P. Vanderloo	23
7	Prion Protein Polymorphisms Affect Chronic Wasting Disease Progression 2011 ·PLoS ONE ·Chad Johnson, Allen Herbst, (unknown), Joshua P. Vanderloo, (unknown), Rick Chappell, Debbie McKenzie	99
8	Stability of unused reconstituted bortezomib in original manufacturer vials 2010 ·Journal of Oncology Pharmacy Practice ·Joshua P. Vanderloo, Marcia Pomplun, Lee C. Vermeulen, Jill Kolesar	26
9	Comparative prion disease gene expression profiling using the prion disease mimetic, cuprizone 2009 ·Prion ·(unknown), Allen Herbst, Han Sang Yoo, Joshua P. Vanderloo, Judd M. Aiken	17
10	Surveillance for Transmissible Spongiform Encephalopathy in Scavengers of White-Tailed Deer Carcasses in the Chronic Wasting Disease Area of Wisconsin 2009 ·Journal of Toxicology and Environmental Health ·Christopher S. Jennelle, Michael D. Samuel, (unknown), Delwyn P. Keane, (unknown), Chad Johnson, Joshua P. Vanderloo, Judd M. Aiken, Amir N. Hamir, Edward A. Hoover	21
11	Prion protein polymorphisms in white-tailed deer influence susceptibility to chronic wasting disease 2006 ·Journal of General Virology ·Chad Johnson, Jody Johnson, Joshua P. Vanderloo, Delwyn P. Keane, Judd M. Aiken, Debbie McKenzie	133

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact